• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bayer Ag Ord (OP: BAYZF )

    26.96 UNCHANGED
    Streaming Delayed Price Updated: 1:38 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bayer Ag Ord

    < Previous 1 2 3 Next >
    Bayer Shares Fall 7% As US Court Reconsiders Monsanto PCB Exposure Case
    German life sciences giant Bayer saw its shares drop by over 7% on Wednesday following a US court’s decision to review a case against Monsanto, a subsidiary acquired by Bayer in 2018. 
    Via Talk Markets
    Futures Rally Fizzles As Dollar, Yields And Oil Slump
    US equity futures erased earlier gains and were trading with modest losses as the dollar, oil, and yields all slumped entering the US session. 
    Via Talk Markets
    Bayer Weedkiller Lawsuit Dismissed By Australian Judge: Insufficient Evidence Linking Roundup To Blood Cancer
    Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance that product is safe. 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Glyphosate Legal
    Judge Slashes Bayer's Massive $2B Roundup Verdict To $400M
    Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the ongoing cancer litigation. 
    Via Benzinga
    Exposures Glyphosate
    After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
    Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications. 
    Via Benzinga
    Topics Data Breach
    Exposures Information Security
    Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
    Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. 
    Via Benzinga
    Bayer's Monsanto Scores Legal Victory as $185M Verdict Overturned
    Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict over chemical contamination. This highlights broader legal battles over PCBs... 
    Via Benzinga
    Exposures Glyphosate
    Bayer's Third Menopausal Relief Drug Trial Meets Primary Goal, German Conglomerate Seeks FDA Approval For Elinzanetant
    Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Results show significant reduction in symptoms over 12 weeks, marking a potential... 
    Via Benzinga
    Exposures Product Safety
    German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
    Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. 
    Via Benzinga
    Topics Bankruptcy Lawsuit
    Exposures Financial Glyphosate Legal
    Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges
    Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing performance and flexibility. The company's focus and fiscal outlook for 2024. 
    Via Benzinga
    What's Going On With BridgeBio Pharma Stock On Monday?
    BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
    Via Benzinga
    Exposures Product Safety
    Weedkiller Woes: Australian Court Nears Decision in Bayer's Roundup Trial
    Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to cancer. 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Glyphosate Legal
    Roundup Cancer Verdict: Woes Continue For Bayer As It Faces $2.2B Payout
    "Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses, and punitive damages. 
    Via Benzinga
    Exposures Glyphosate
    Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
    Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
    Via Benzinga
    Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
    Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF)  
    Via Benzinga
    Bayer Study On Parkinson's Disease Gene Therapy Succeeds In Early-Stage Trial
    Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's. 
    Via Benzinga
    Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
    In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce Jones, who alleged that the use of Roundup caused his non-Hodgkin... 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Glyphosate Legal
    ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
    With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience... 
    Via Benzinga
    Topics Climate Change
    Exposures Climate
    Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
    Bayer AG (OTC: BAYRY) (OTC:  
    Via Benzinga
    Exposures Glyphosate
    Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
    The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts  
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Glyphosate Legal
    German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
    Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about... 
    Via Benzinga
    Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
    Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
    Via Benzinga
    Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
    Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
    Via Benzinga
    Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
    The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
    Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced  
    Via Benzinga
    Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
    Bayer AG (OTC: BAYRY) (OTC:  
    Via Benzinga
    Exposures Glyphosate
    From Years to Months: How AI is Shaping the Landscape of Clinical Trials
    Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
    Reuters 
    Via Benzinga
    German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
    Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
    Via Benzinga
    FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
    The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.